- $946.96m
- $957.97m
- $713.14m
- 36
- 68
- 61
- 55
Annual income statement for Opko Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,435 | 1,775 | 1,004 | 863 | 713 |
| Cost of Revenue | |||||
| Gross Profit | 541 | 582 | 288 | 318 | 219 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,378 | 1,756 | 1,230 | 1,021 | 865 |
| Operating Profit | 57.7 | 18.8 | -226 | -157 | -152 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 48.7 | -14 | -392 | -184 | -10.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 31.1 | -29.5 | -328 | -189 | -53.2 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 30.6 | -30.1 | -328 | -189 | -53.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 30.6 | -30.1 | -328 | -189 | -53.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.049 | -0.078 | -0.473 | -0.251 | -0.19 |